Home
Hege Fredriksen Berg's picture

Hege Fredriksen Berg

Postdoctoral Fellow
  • E-mailhege.berg@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

I earned my PhD at the University of Bergen on organoid models and novel biomarkers for improved treatment of endometrial cancer. I am currently a postdoctoral fellow in the Bergen Gynecological Research Group, where my main focus is to study drug resistance and identify new treatment strategies for endometrial cancer patients. Currently, I am working on a study that applies advanced functional genomics to identify genes responsible for carboplatin resistance. This new knowledge will be used to find novel treatments for chemotherapy resistant endometrial cancers.

Academic article
  • Show author(s) (2023). Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease. EBioMedicine. 14 pages.
  • Show author(s) (2022). Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value. British Journal of Cancer. 647-655.
  • Show author(s) (2021). Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. Communications Medicine. 1-14.
  • Show author(s) (2021). Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer. Journal of Translational Medicine. 1-13.
  • Show author(s) (2021). A radiogenomics application for prognostic profiling of endometrial cancer. Communications Biology. 12 pages.
  • Show author(s) (2020). Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers. 1-18.
  • Show author(s) (2020). Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecologic Oncology. 1-9.
  • Show author(s) (2020). High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • Show author(s) (2020). Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer. 1014-1022.
  • Show author(s) (2019). Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. PLOS ONE. 1-13.
  • Show author(s) (2018). Blood steroids are associated with prognosis and fat distribution in endometrial cancer. Gynecologic Oncology. 46-52.
  • Show author(s) (2017). HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • Show author(s) (2017). Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecologic Oncology. 197-203.
Errata
  • Show author(s) (2023). Corrigendum to “Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease” [EBioMedicine 92 (2023) 104595] (eBioMedicine (2023) 92, (S2352396423001603), (10.1016/j.ebiom.2023.104595)). EBioMedicine.

More information in national current research information system (CRIStin)